原发性肝癌、肝硬化患者血清中丙肝病毒抗体的检测

Antibodies to Hepatitis C Virus among Patients with Hepatocellular Carcinoma and Cirrhosis of Liver

应用国产ELISA试剂盒对157例肝癌、肝硬化病人血清中抗-HCV及HBV-M进行检测，101例肝癌10例抗-HCV阳性，阳性率为9．9％；56例肝硬化6例抗-HCV阳性，阳性率为10．7％；肝癌组抗HCV与HBsAg双阳性率79％（8／101），HBsAg阳性率为723％（73／101），明显高于HCV感染率，说明HBV仍是乙肝流行地区的主要相关因素。14例抗-HCV阳性（包括可疑阳性），肝癌外周血中8例（57．1％）HBsAg阳性，推测HCV可单独作用但更常与HBV形成混合感染参与慢性肝病的癌变过程。

Sera from patients with hepatocellular carcinoma and cirrhosis of liver were tested for antibodies to hepatitis C Virus (anti-HCV) and hepatitis B virus markers by using an enzyme-linked immunosorbent assay (ELISA). Among 101 patients with HCC,anti-HCV was positive in 10(9. 9% ). In 56 patients with cirrhosis,anti-HCV was positive in 6(10. 7% ). Both anti-HCV and HBsAg were positive in 7. 9% (8/101 )of patients with HCC HBsAg positive in patients with HCC was 72. 3% (73/101). The results show that HBV infection is still a main factor in the development of HCC. In 14 patients who were positive for anti-HCV,8(57. 1 %)were positive for HbsAg These findings suggest that coinfection of HBV and HCV may play the rloe in the pathogenesis of HCC.